0102030405
COBIMETINIB(XL518) CAS No.934660-93-2 Pharmaceutical Intermediates
02
introduction
Cobimetinib (XL518) is an oral medication classified as a MEK inhibitor, primarily indicated for the treatment of patients with advanced melanoma, especially those with BRAF V600E or V600K mutations.
By inhibiting the MEK1 and MEK2 proteins, Cobimetinib disrupts the MAPK signaling pathway, which is often overactive in cancer cells, leading to uncontrolled growth and proliferation.
This targeted approach not only helps in controlling tumor growth but also minimizes damage to normal cells, making it a valuable option in cancer therapy.
By inhibiting the MEK1 and MEK2 proteins, Cobimetinib disrupts the MAPK signaling pathway, which is often overactive in cancer cells, leading to uncontrolled growth and proliferation.
This targeted approach not only helps in controlling tumor growth but also minimizes damage to normal cells, making it a valuable option in cancer therapy.
02
Physical and chemical properties
- Solubility: Cobimetinib (XL518) is soluble in organic solvents and has moderate solubility in water, facilitating its formulation into tablets and ensuring effective absorption in the gastrointestinal tract.
- Stability: The compound exhibits good stability under standard storage conditions, ensuring a longer shelf life and reliability in pharmaceutical applications.
These properties not only enhance the efficacy of Cobimetinib (XL518) in clinical settings but also contribute to its overall safety profile.
- Stability: The compound exhibits good stability under standard storage conditions, ensuring a longer shelf life and reliability in pharmaceutical applications.
These properties not only enhance the efficacy of Cobimetinib (XL518) in clinical settings but also contribute to its overall safety profile.
1. Targeted Cancer Therapy: Cobimetinib (XL518) specifically targets the MEK proteins, providing a focused approach to inhibit cancer cell growth while sparing normal cells.
2. Enhanced Treatment Efficacy: When used in combination with other therapies, such as BRAF inhibitors, Cobimetinib (XL518) has been shown to improve overall treatment outcomes for patients with advanced melanoma.
3. Convenient Oral Administration: Available in tablet form, Cobimetinib (XL518) offers a convenient route of administration, improving patient compliance and ease of use.
4. Established Safety Profile: Cobimetinib (XL518) has undergone extensive clinical trials, providing a well-established safety profile when administered under proper medical supervision.
5. Regulatory Compliance: Our Cobimetinib (XL518) products adhere to all relevant regulatory standards, ensuring they are suitable for use in pharmaceutical applications worldwide.
2. Enhanced Treatment Efficacy: When used in combination with other therapies, such as BRAF inhibitors, Cobimetinib (XL518) has been shown to improve overall treatment outcomes for patients with advanced melanoma.
3. Convenient Oral Administration: Available in tablet form, Cobimetinib (XL518) offers a convenient route of administration, improving patient compliance and ease of use.
4. Established Safety Profile: Cobimetinib (XL518) has undergone extensive clinical trials, providing a well-established safety profile when administered under proper medical supervision.
5. Regulatory Compliance: Our Cobimetinib (XL518) products adhere to all relevant regulatory standards, ensuring they are suitable for use in pharmaceutical applications worldwide.
In addition to our high-quality Cobimetinib (XL518), we also provide a range of laboratory equipment and supplies essential for pharmaceutical research and development. Our offerings include:
- High-Performance Liquid Chromatography (HPLC) Systems: Ideal for analyzing the purity and composition of pharmaceutical compounds, including Cobimetinib (XL518).
- Mass Spectrometry (MS) Instruments: Essential for determining molecular weights and structural information of active pharmaceutical ingredients (APIs).
- Reagents and Solvents: A comprehensive selection of high-purity reagents and solvents to support various chemical reactions and analyses.
- High-Performance Liquid Chromatography (HPLC) Systems: Ideal for analyzing the purity and composition of pharmaceutical compounds, including Cobimetinib (XL518).
- Mass Spectrometry (MS) Instruments: Essential for determining molecular weights and structural information of active pharmaceutical ingredients (APIs).
- Reagents and Solvents: A comprehensive selection of high-purity reagents and solvents to support various chemical reactions and analyses.
In conclusion, the Cobimetinib(XL518) is a vital compound for laboratories engaged in pharmaceutical and microbiological research. Its high purity, stability, and versatility make it an essential reagent for scientists seeking to advance their understanding of antibiotic mechanisms and resistance.
As a leading foreign trade company, we are committed to providing our clients with top-quality products and unparalleled support, ensuring that they can achieve their research goals efficiently and effectively.
Choosing our Cobimetinib (XL518) means partnering with a reliable supplier committed to quality, efficiency, and customer satisfaction.
Contact us today to learn more about how our Cobimetinib (XL518) can enhance your drug development processes and contribute to your success in the pharmaceutical market.
As a leading foreign trade company, we are committed to providing our clients with top-quality products and unparalleled support, ensuring that they can achieve their research goals efficiently and effectively.
Choosing our Cobimetinib (XL518) means partnering with a reliable supplier committed to quality, efficiency, and customer satisfaction.
Contact us today to learn more about how our Cobimetinib (XL518) can enhance your drug development processes and contribute to your success in the pharmaceutical market.